Eden Research plc (AIM: EDEN) delivered strong preliminary 2024 financial results, with revenue up 34% year-on-year and product sales growing 38%, driven by expanding regulatory approvals and commercial momentum across key markets. The company, a leader in sustainable crop protection solutions, strengthened its portfolio with major label extensions for its flagship biofungicide Mevalone in Spain, Germany, and California, and secured important progress toward full approval of its seed treatment product Ecovelex with strategic partner Corteva.

Operational highlights included broadening the addressable market, new authorizations for Mevalone in critical territories, and robust commercial trial activity supporting the next-generation insecticide product, which is attracting strong interest from multiple global partners. Eden also reinforced its commercial and regulatory teams to accelerate growth and capitalize on opportunities arising from tightening pesticide regulations and rising demand for sustainable agriculture.

Looking ahead, Eden forecasts £5 million in revenue for 2025, with potential upside from pending regulatory approvals and commercial milestones. The company maintains a healthy cash position and does not expect to raise additional funds for existing working capital requirements. Eden’s growth strategy remains focused on expanding its global footprint, launching new biopesticide products, and scaling partnerships to drive revenue and profitability. With strong industry tailwinds, a deep product pipeline, and proven commercial execution, Eden Research is well-positioned to deliver long-term value for shareholders as regulatory and consumer demand reshapes the global crop protection market.

HydrogenOne Capital Growth PLC (LSE: HGEN) has delivered its Q1 2025 investor update, reporting stable NAV at £115 million and 21% year-over-year portfolio revenue growth, reaching £92 million. Despite macroeconomic headwinds, portfolio companies such as Sunfire, HighRock, and Cranfield show strong operational progress, bolstered by major developments like HighRock’s new joint venture and Sunfire’s €200 million financing. The fund remains committed to scaling clean energy infrastructure, with a strategic focus on energy transition supply chain businesses. HydrogenOne also released its Hydrogen Handbook, highlighting a 15x expected increase in green hydrogen supply by 2027 and significant government policy support globally. Management confirmed proactive steps to address the NAV discount, including appointing Shore Capital as financial advisor. With robust portfolio momentum, improving margins, and an expanding order book, HydrogenOne is well-positioned to capitalize on the accelerating demand for clean hydrogen solutions.

Diaceutics PLC (AIM: DXRX) delivered a strong performance in FY2024, marking a breakout year driven by business transformation, robust financial results, and a clear growth strategy. Revenue increased by 39% on a constant currency basis to £32 million, with gross margins rising to 88% and annual recurring revenue (ARR) growing 23% to £16.8 million. The company secured three new multi-year enterprise-wide engagements, expanded its order book to £24.9 million, and strengthened its presence with 18 of the top 20 global pharma companies. Diaceutics continues to scale its DXRX platform, leveraging AI-driven solutions and its proprietary lab network to drive deeper customer integration and recurring revenue growth. The successful launch of the PMX commercialization solution highlights significant revenue potential, boosting average revenue per brand to over £3 million. With a strong balance sheet, no debt, and a focused US market expansion, Diaceutics is positioned to deliver high-margin, recurring revenue growth, increased EBITDA, and profitability in FY2025 and beyond, despite a dynamic macroeconomic backdrop.

NAHL Group plc (AIM: NAH) delivered resilient 2024 financial results despite a challenging trading environment in personal injury markets. Group revenue declined 8% to £38.8 million, primarily reflecting lower inquiry volumes, but underlying profit before tax increased 113% to £1.4 million. Strong cash generation continued, with £2.6 million of free cash flow driving a 27% reduction in net debt to £7.1 million. The group's Consumer Legal Services division matured its in-house law firm, National Accident Law, delivering record settlements and enhanced margins, while Critical Care (Bush & Co) grew revenues by 9% and operating profits by 10%. Strategic initiatives included optimizing marketing spend, leveraging AI to improve inquiry acquisition, and advancing operational efficiencies. NAHL remains focused on reducing debt, unlocking shareholder value, and progressing the potential sale of Bush & Co. With a robust pipeline, strong order book, and continued EBITDA growth, NAHL is well-positioned for sustainable long-term performance.

Downing Renewables & Infrastructure Trust PLC (DORE) delivered a robust investor update, highlighting resilient company performance, strong financial results, and strategic asset optimization. For the year ended 31 December 2024, DORE achieved a NAV total return close to 40% since IPO, with a 1.2x dividend cover and a portfolio-wide gross return of 11.4%. The Trust completed the highly successful sale of its Gabriel wind farm, delivering a 54% return, expanded its hydro portfolio, and continued optimizing grid and solar assets. DORE’s diversified renewable energy portfolio across the UK and Nordics—with significant hydro, solar, and grid infrastructure assets—remains well positioned for growth, benefiting from inflation-linked revenues and long-term regulatory drivers. The Trust also strengthened its balance sheet, maintaining zero RCF debt and increasing its 2025 dividend target to 5.95p, offering a 7% yield. With an 8% portfolio discount rate and a clear growth strategy focused on asset optimization, selective acquisitions, and sustainability leadership, DORE continues to deliver resilient shareholder value in a challenging market environment.

Venture Life Group (VLG) has announced a significant strategic shift, divesting its CDMO operations in Italy and Sweden, along with peripheral brands, for €62 million to Byodua. This move simplifies VLG into a pure-play branded consumer healthcare platform, enhancing its focus on high-margin, high-growth products. The transaction, valued at around 11x EBITDA, will improve cash flow, margins, and reduce capital intensity, while maintaining long-term manufacturing agreements to ensure supply continuity. VLG will reinvest proceeds into expanding its "power brands," targeting accelerated revenue growth, enhanced EBITDA margins, and strategic M&A at attractive multiples. With a strong presence in women's and men's health, a growing US retail footprint, and advanced digital capabilities, VLG aims to drive innovation, increase its Vitality Index to 20%, and deliver superior shareholder value. This transformation positions Venture Life for sustainable, profitable growth and a higher market valuation, supported by a scalable, data-driven growth strategy focused on proactive health and longevity.

Likewise PLC delivered a strong investor update, reporting 7.4% revenue growth in FY24 to £150 million, with Likewise Floors achieving an impressive 15.5% sales increase. Gross margins improved to 30.7%, underlying EBITDA rose to £8.8 million, and the group generated £7.2 million in positive cash flow. Supported by significant investment in logistics, an expanded distribution network, and strategic partnerships with leading flooring brands, Likewise is building operational leverage and targeting ambitious future growth. The company highlighted accelerating revenue momentum, with like-for-like sales up 11.5% in early 2025, driven by a strong order book, a robust market presence across the UK, and expanded customer reach. Management reiterated confidence in achieving over £200 million revenue in the coming years, backed by a debt-light balance sheet, substantial property assets, and ongoing investment in new product development and sales teams. A share buyback program has been launched, underlining the board’s commitment to enhancing shareholder returns while maintaining a disciplined growth strategy. Likewise continues to prioritize organic expansion, margin improvement, and operational efficiency, positioning itself as a market leader in the UK flooring distribution sector.

ACG Metals, a newly listed company on the London Stock Exchange, has delivered an impressive update, highlighting strong financial results, a fully funded growth strategy, and substantial near-term upside. Led by a seasoned team with a proven track record in mining M&A and asset development, ACG Metals generated nearly $90 million in free cash flow in 2024, maintains $190 million in cash reserves, and is advancing the sulphide expansion at its flagship Turkish asset. The company boasts a low-cost, high-grade resource base, securing first-quartile margins across gold, silver, copper, and zinc production. With a $200 million bond successfully raised and construction progressing on time and on budget, ACG is poised for a step-change in EBITDA and revenue as copper production commences in early 2026. Trading at a significant discount to peers—around 1x 2024 cash flow—the company’s growth plan includes strategic M&A targeting cash-generative assets in key copper belts. Backed by world-class partners, a strong order book, and a disciplined balance sheet, ACG Metals offers investors a rare combination of cash flow strength, margin expansion, and transformational growth potential.

GETECH  has announced its financial results for FY2024, reporting 16% revenue growth to £4.7 million, driven by strong contract renewals and services revenue, despite a reduced loss. Under a new leadership team, GTech has swiftly implemented a sustainable business strategy focused on rebalancing finances, reducing annualised costs by £3 million, completing a successful £1.7 million placing, and becoming debt-free through asset sales. The company is refocusing on core markets—oil and gas, mining, and emerging sectors like natural hydrogen—while enhancing its Globe digital exploration platform with AI and machine learning capabilities. GTech’s strengthened financial position, expanded sales team, and pipeline of major multi-year opportunities position it for mid to high single-digit organic revenue growth in 2025. With a focus on growing annual recurring revenue (ARR), leveraging proprietary IP, and advancing strategic natural hydrogen joint ventures, GTech aims to deliver sustainable EBITDA growth and enhanced shareholder value. The company’s streamlined structure, premium client base, and differentiated technology platforms provide a strong foundation for long-term performance.